“We leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.”

We have a long history in bringing cancer therapies to market:

• 1977: Launched Krestin (Polysaccharide-K) in Japan to treat digestive, lung and breast cancer.
• 1985: Launched the first natural-type interferon beta preparations for brain tumour and skin cancer in Japan.
• 1995: Received approval of irinotecan in Japan, the first chemotherapy to demonstrate survival benefits in colorectal cancer.
• 2012: Launched Renmark (denosumab) in Japan for treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumours.
• 2012: First BRAF inhibitor to be coupled.
• Today: >20 compounds directed at a range of unmet needs, including AML, breast and gastric cancers and tenosynovial giant cell tumour (TGCT).

Our compounds in development include:

• ADC Franchise: DS-8201a an antibody drug conjugate (ADC) for HER2-expressing breast and gastric cancer, and other HER2-expressing solid tumours.
• AML Franchise: Quizartinib, an oral FLT3 inhibitor for newly-diagnosed and relapsed or refractory AML with FLT3-ITD mutations.
• Breakthrough Science Franchise: Pexidartinib, an oral CSF-1R inhibitor for TGCT, which is also being explored in a range of solid tumours in combination with the anti-PD1 immunotherapy pembrolizumab.